Appendix B

Clean copy of claims pending

1	1. (Amended) A conjugate comprising a drug coupled with an isolated peptide
2	sequence selected from the group consisting of SEQ ID Nos. 1-8.
1	2. (Amended) The conjugate of claim 1, said isolated peptide sequence having
2	from 4-30 amino acid residues.
1	6. The conjugate of claim 1, said drug selected from a class of drugs consisting of
2	anti-inflammatory agents, antitumor agent, oligonucleotides, cytokines, enzyme
3	inhibitors, and vasoregulator agents.
1	7. The conjugate of claim 1 said drug selected from the group consisting of
2	methotrexate, lovastatin, taxol, ajmalicine, vinblastine, vincristine, cyclophosphamide,
3	fluorouracil, idarubicin, ifosfamide, irinotecan, 6-mercaptopurine, mytomycins,
4	mitoxantrone, paclitaxel, taxol, pentostatin, plicamycin, topotecan, fludarabine,
5	etoposide, doxorubicin, doxotaxel, danorubicin, albuterol, and propidium.
1	8. The conjugate of claim 1, said drug being methotrexate.
1.	9. (Amended) The conjugate of claim 1, said isolated peptide sequence having at
2	least about 50% homology with at least one of said SEQ ID Nos. 1-8.
•	
1	35. The conjugate of claim 1, said conjugate characterized by the ability of
2	binding to surface receptors of target cells and subsequently being internalized by said
3	target cells.



- 37. (Amended) The conjugate of claim 1, wherein the a drug is coupled with an isolated peptide sequence of SEQ ID NO. 8. wherein the peptide sequence further comprises penicillamine.
- 1 38. The conjugate of claim 1, said isolated peptide sequence being cyclic.
- 42. A conjugate comprising a first portion and a second portion, wherein said first portion is a peptide and said second portion is a drug, said peptide being derived from ICAM-1 or LFA-1 and being characterized by binding to LFA-1 and ICAM-1 receptors on leudocytes and by being internalized by cells expressing at least one of said receptors.